-
Weekly Pharma News Review | PharmaSources.com (May. 23th - May. 29th)
Industry Data
PharmaSources.comMay 31, 2022
This week, a steady flow of good news kept pouring into the Chinese pharmaceutical market. The local "first-in-class" Benvimod was successfully approved by FDA while Hengrui's SHR3680 tablets in treating prostate cancer had a successful Phase III clinical
-
3D Printing: A Perfect Storm for Pharma Industry and Regulatory Agency
Industry Data
PharmaSources/Eric Sun, Ph.D.April 12, 2022
3D printing or additive manufacturing is a process of creating three-dimensional solid objects from a digital design. The process involves printing sequentially thin layers of the building materials until the object is created.
-
Synthesis technology of cepharanthine, a "specific drug" for coronavirus
Industry Data
PharmaSources/YuntianMay 25, 2022
Recently, cepharanthine, first discovered in China as the new drug for treating COVID-19, has recently been granted the national invention patent authorization, which has drawn great attention from inside and outside the industry.
-
New Improvement in Universal Vaccines and Long-acting Neutralizing Antibodies
Industry Data
PharmaSources/YefenghongMay 25, 2022
COVID-19 has spread rapidly since the winter of 2019, and even today, the whole world is still shrouded in its haze.
-
Weekly Pharma News Review | PharmaSources.com （May.16th - 20th）
Industry Data
PharmaSources.comMay 25, 2022
The first therapeutic effect data of VV116, a small-molecule oral drug for COVID-19 of Junshi Biosciences and Vigonvita, was released this week, captivating the industry.
-
Is mRNA Vaccine the Source of Intricacies of "Mysterious Hepatitis"?
Industry Data
PharmaSources/YefenghongMay 23, 2022
3 years into the COVID-19 pandemic, it has had a significant impact on human health and economic development. Based on WHO statistics, as of April 22, there are approximately 497 million confirmed patients and 6.179 million deaths in the world because of
-
IPOs Review of Chinese Biomedical Companies in 2021
Industry Data
May 23, 2022
In 2021, there are 89 Chinese biomedical companies (according to the classification of "Pharmaceutical and Biological" based on the industry division method of Shenyin & Wanguo Securities) completed IPOs in the Chinese mainland, Hong Kong Region of China,
-
Chinese Pharmaceutical Companies Entering the DC Vaccine Market Under the Support of Tens of Millions of Financing
Industry Data
PharmaSources/YefenghongMay 23, 2022
Which can be applied to the treatment of cancers and even the COVID-19 infection.
-
First Drug Coming Soon as Pharmaceutical Companies Take Moves in the B7-H3 Immune Target Products Layout
Industry Data
PharmaSources.com/YiMay 23, 2022
Based on public information, TAA06 is an independently developed B7-H3-targeted CAR-T therapy of PersonGen. The drug was granted the Orphan Drug Designation (ODD) for treating neuroblastoma by the FDA (Food and Drug Administration) in March of this year.
-
With First Chinese Small-molecule Oral Drug for COVID-19 Coming, What New Opportunities are Ushered in by the Relevant Industry Chain？
Industry Data
PharmaSources.com/YefenghongMay 23, 2022
News about the progress of Chinese small-molecule oral antiviral drug for COVID-19 has been disclosed in recent days and the related R&D ushers in a critical point.
This week, a steady flow of good news kept pouring into the Chinese pharmaceutical market. The local "first-in-class" Benvimod was successfully approved by FDA while Hengrui's SHR3680 tablets in treating prostate cancer had a successful Phase III clinical
3D printing or additive manufacturing is a process of creating three-dimensional solid objects from a digital design. The process involves printing sequentially thin layers of the building materials until the object is created.
Recently, cepharanthine, first discovered in China as the new drug for treating COVID-19, has recently been granted the national invention patent authorization, which has drawn great attention from inside and outside the industry.
COVID-19 has spread rapidly since the winter of 2019, and even today, the whole world is still shrouded in its haze.
The first therapeutic effect data of VV116, a small-molecule oral drug for COVID-19 of Junshi Biosciences and Vigonvita, was released this week, captivating the industry.
3 years into the COVID-19 pandemic, it has had a significant impact on human health and economic development. Based on WHO statistics, as of April 22, there are approximately 497 million confirmed patients and 6.179 million deaths in the world because of
In 2021, there are 89 Chinese biomedical companies (according to the classification of "Pharmaceutical and Biological" based on the industry division method of Shenyin & Wanguo Securities) completed IPOs in the Chinese mainland, Hong Kong Region of China,
Which can be applied to the treatment of cancers and even the COVID-19 infection.
Based on public information, TAA06 is an independently developed B7-H3-targeted CAR-T therapy of PersonGen. The drug was granted the Orphan Drug Designation (ODD) for treating neuroblastoma by the FDA (Food and Drug Administration) in March of this year.
News about the progress of Chinese small-molecule oral antiviral drug for COVID-19 has been disclosed in recent days and the related R&D ushers in a critical point.
Pharma Sources Insight JUNE2022
